NCT00451217View on ClinicalTrials.gov

Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)

PHASE3CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

November 17, 2005

Primary Completion Date

March 6, 2006

Study Completion Date

March 6, 2006

Conditions
Anesthesia, General
Interventions
DRUG

Sugammadex

After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg sugammadex was to be administered

DRUG

Neostigmine

After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00451217 - Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960) | Biotech Hunter | Biotech Hunter